russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2017-5-85-90russjcardiol-2320Research ArticleОФИЦИАЛЬНАЯ ИНФОРМАЦИЯINFORMATIONРЕЗУЛЬТАТЫ КЛИНИЧЕСКОГО ИССЛЕДОВАНИЯ FOURIER. НОВЫЕ ВОЗМОЖНОСТИ ЛЕЧЕНИЯ ПАЦИЕНТОВ ОЧЕНЬ ВЫСОКОГО СЕРДЕЧНО-СОСУДИСТОГО РИСКАRESULTS OF THE CLINICAL TRIAL FOURIER. NEW OPPORTUNITIES FOR TREATMENT OF VERY HIGH CARDIOVASCULAR RISK PATIENTSСоветЭкспертовBoardAdvisory

Президиум экспертного совета: Бойцов С.А. (Москва), Карпов Ю. А. (Москва), Ежов М. В. (Москва).

Эксперты: Алекян Б. Г. (Москва), Ахмеджанов Н.М. (Москва), Бажан С. С. (Новосибирск), Бубнова М. Г. (Москва), Воевода М. И. (Новосибирск), Гуревич В.С. (Санкт-Петербург), Ершова А.И. (Москва), Кашталап В.В. (Кемерово), Коновалов Г. А. (Москва), Константинов В. О. (Санкт-Петербург), Кухарчук В. В. (Москва), Мешков А. Н. (Москва), Сергиенко И. В. (Москва), Шальнова С. А. (Москва). 

Chairs of the Advisory Board: Boytsov S. А. (Moscow), Karpov Yu. А. (Moscow), Ezhov М. V. (Moscow).

Experts: Alekian B. G. (Moscow), Akhmedzhanov N. М. (Moscow), Bazhan S. S. (Novosibirsk), Bubnova M. G. (Moscow), Voevoda М. I. (Novosibirsk), Gurevich V. S. (Saint-Petersburg), Ershova А. I. (Moscow), Kashtalap V. V. (Kemerovo), Konovalov G. А. (Moscow), Konstantinov V. О. (Saint-Petersburg), Kukharchuk V.V. (Moscow), Meshkov А.N. (Moscow), Sergienko I.V. (Moscow), Shalnova S. А. (Moscow). 

Российское кардиологическое общество (РКО); Национальное общество по изучению атеросклероза (НОА); Российское общество кардиосоматической реабилитации и вторичной профилактики (РосОКР)РоссияBoard of Russian Society of Cardiology (RSC); Russian National Atherosclerosis Society (RNAS); Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention (RSCRSP)Russian Federation201709062017058590Copyright © Совет Э., 20172017Совет Э.Board A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/2320

Совет Экспертов Российского кардиологического общества (РКО), Национального общества по изучению атеросклероза (НОА), Российского общества кардиосоматической реабилитации и вторичной профилактики (РосОКР) 

Advisory Board of Russian Society of Cardiology (RSC), Russian National Atherosclerosis Society (RNAS), Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention (RSCRSP) 

FOURIERэволокумабгиполипидемическая терапияFOURIERevolocumabhypolipidemic therapyReferencesKotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016; 23 (6): 636-48.Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016; 23 (6): 636-48.Oganov RG, Kukharchuk VV, Arutyunov GP, et al. Persistent violations of lipid spectrum in patients with dyslipidemia receiving statins in clinical practice in the Russian Federation (the Russian part of the study DYSIS). Cardiovascular Therapy and Prevention. 2012; 11 (4): 70-8. Russian (Оганов Р. Г., Кухарчук В. В., Арутюнов Г. П. и др. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в российской федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика. 2012; 11 (4): 70-8).Oganov RG, Kukharchuk VV, Arutyunov GP, et al. Persistent violations of lipid spectrum in patients with dyslipidemia receiving statins in clinical practice in the Russian Federation (the Russian part of the study DYSIS). Cardiovascular Therapy and Prevention. 2012; 11 (4): 70-8. Russian (Оганов Р. Г., Кухарчук В. В., Арутюнов Г. П. и др. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в российской федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика. 2012; 11 (4): 70-8).Cholesterol Treatment Trialists’ (CTT) Collaboration et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.Cholesterol Treatment Trialists’ (CTT) Collaboration et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.Brown MS, Goldstein JL. Cholesterol feedback: from Schoenheimer’s bottle to Scap’s MELADL. J Lipid Res. 2009; 50 (suppl): S15-S27.Brown MS, Goldstein JL. Cholesterol feedback: from Schoenheimer’s bottle to Scap’s MELADL. J Lipid Res. 2009; 50 (suppl): S15-S27.Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009;106: 9820-5.Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009;106: 9820-5.Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderateor high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014; 311(18): 1870-82.Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderateor high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014; 311(18): 1870-82.Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017. doi: 10.1001/jamacardio.2017.0747. [Epub ahead of print].Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017. doi: 10.1001/jamacardio.2017.0747. [Epub ahead of print].Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016; 316 (22): 2373-84.Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016; 316 (22): 2373-84.Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Pati ents with Cardiovascular Disease. N Engl J Med. 2017. doi: 10.1056/NEJMoa1615664. [Epub ahead of print].Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Pati ents with Cardiovascular Disease. N Engl J Med. 2017. doi: 10.1056/NEJMoa1615664. [Epub ahead of print].Giugliano RP, Mach F, Zavitz Kv, et al. EBBINGHAUS:-A Cognitive Study of Patients Enrolled in the FOURIER Trial. Presented at the American College of Cardiology, Washington, 2017.Giugliano RP, Mach F, Zavitz Kv, et al. EBBINGHAUS:-A Cognitive Study of Patients Enrolled in the FOURIER Trial. Presented at the American College of Cardiology, Washington, 2017.Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37 (39): 2999-3058.Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37 (39): 2999-3058.Landmesser U, John Chapman M, Farnier M, et al. European Society of Cardiology/ European Atherosclerosis Society Task Force consensus statement on proprotein conve rtase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. 2016. pii: ehw480. [Epub ahead of print].Landmesser U, John Chapman M, Farnier M, et al. European Society of Cardiology/ European Atherosclerosis Society Task Force consensus statement on proprotein conve rtase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. 2016. pii: ehw480. [Epub ahead of print].Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015 May 1; 36 (17): 1012-22.Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015 May 1; 36 (17): 1012-22.Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372: 2387-97.Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372: 2387-97.Suárez C, Zeymer U, Limbourg T, et al. Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry. Vasc Med. 2010 Aug; 15 (4): 259-65.Suárez C, Zeymer U, Limbourg T, et al. Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry. Vasc Med. 2010 Aug; 15 (4): 259-65.Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010; 304 (12): 1350-7.Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010; 304 (12): 1350-7.Sokolov AA, Aleksandrova OYu, Kashtalap VV, et al. Methodical recommendations on organization of medical aid to patients with hereditary atherogenic disorders of the lipid metabolism in subjects of the Russian Federation. Atherosclerosis and dyslipidemia 2016; 4, 25: 14-20. Russian (Соколов А. А., Александрова О. Ю., Кашталап В. В. и др. Методические рекомендации по организации медицинской помощи больным с наследственными атерогенными нарушениями липидного обмена в субъектах РФ. Атеросклероз и дислипидемии 2016; 4, 25: 14-20).Sokolov AA, Aleksandrova OYu, Kashtalap VV, et al. Methodical recommendations on organization of medical aid to patients with hereditary atherogenic disorders of the lipid metabolism in subjects of the Russian Federation. Atherosclerosis and dyslipidemia 2016; 4, 25: 14-20. Russian (Соколов А. А., Александрова О. Ю., Кашталап В. В. и др. Методические рекомендации по организации медицинской помощи больным с наследственными атерогенными нарушениями липидного обмена в субъектах РФ. Атеросклероз и дислипидемии 2016; 4, 25: 14-20).

The authors declare that there are no conflicts of interest present.